Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment : Results from the CLEAR study
-
Thaçi, Diamant (Research Institute and Comprehensive Center for Inflammation Medicine. University of Luebeck)
;
Puig Sanz, Lluís. (Institut d'Investigació Biomèdica Sant Pau) ;
Reich, Kristian (Dermatologikum Berlin and SCIderm Research Institute) ;
Tsai, T. F. (National Taiwan University Hospital (Taipei, Taiwan)) ;
Tyring, S. (University of Texas Health Science Center and Center for Clinical Studies) ;
Kingo, Külli (Tartu University Hospital (Tartu, Estònia)) ;
Ziv, M. (Emek Medical Center) ;
Pinter, Andreas (Department of Dermatology. University of Frankfurt) ;
Vender, Ronald (Venderm Innovations in Psoriasis) ;
Lacombe, A. (Novartis Pharma AG) ;
Xia, Shang (Novartis Beijing Novartis Pharma Co Ltd) ;
Bhosekar, V. (Novartis Healthcare Pvt Ltd) ;
Gilloteau, I. (Novartis Pharma AG) ;
Guana, Adriana (Novartis Pharmaceuticals Corporation) ;
Blauvelt, Andrew (Oregon Medical Research Center) ;
Universitat Autònoma de Barcelona